Related Experiment Videos
Fanconi's syndrome due to ifosfamide
C Beckwith1, K K Flaharty, A K Cheung
1University of Utah College of Pharmacy, Salt Lake City 84112.
Bone Marrow Transplantation
|January 1, 1993
Summary
Fanconi's syndrome is a rare but serious kidney complication of ifosfamide chemotherapy. This case highlights that it can occur even after prior non-toxic exposure, emphasizing the need for vigilant monitoring.
Area of Science:
- Nephrology
- Oncology
- Pharmacology
Background:
- Ifosfamide chemotherapy is increasingly used in high-dose regimens before hematopoietic stem cell transplantation (HSCT).
- Renal phosphate wasting is a known complication, but Fanconi's syndrome is a rare manifestation.
- Previous ifosfamide exposure does not preclude the development of Fanconi's syndrome.
Observation:
- A patient developed Fanconi's syndrome following ifosfamide chemotherapy.
- The patient had no apparent toxicity during prior ifosfamide exposure.
- This case underscores the potential for delayed or unpredicted toxicity.
Findings:
- Fanconi's syndrome can develop subsequent to ifosfamide treatment.
- The syndrome may manifest despite previous uneventful exposure to the drug.
- Increased use of high-dose ifosfamide regimens may lead to a rise in Fanconi's syndrome incidence.
Implications:
- Close patient monitoring for renal dysfunction is crucial during and after ifosfamide chemotherapy.
- Prompt and aggressive management of electrolyte and fluid imbalances is essential.
- Early detection and intervention can mitigate morbidity associated with Fanconi's syndrome.